Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
STAMPEDE: adding 2yr abiraterone to ADT+RT in high-risk M0 prostate cuts MFS (HR 0.53) and OS (HR 0.60); enzalutamide adds nothing.
Prostate carried the day. A pooled STAMPEDE analysis moves 2yr abiraterone onto the ADT+RT backbone for high-risk M0 disease (6-yr MFS 82% vs 69%). RT was mandated for N0, so this is the curative population radoncs already treat; adding enzalutamide gave no incremental MFS.
read the full digest →Studies · 100
- STAMPEDE: abiraterone + prednisolone ± enzalutamide, high-risk non-metastatic prostate cancerMFS HR 0.53 and OS HR 0.60 adding 2yr abiraterone to ADT+RT in high-risk M0 prostate.
- TREASUREOS 6.7 vs 13.4mo (HR 1.55, ns), SAEs 61% vs 18% adding consolidative TRT to atezo maintenance in ES-SCLC; stopped early for toxicity.
- EANO Consensus Statement on Radiation NecrosisRN affects 4-30% of irradiated brain-tumor pts at 6-24mo; perfusion MRI + amino-acid PET for dx, bevacizumab for steroid-refractory cases.
- ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate CancerEducational round-up on SBRT (5fx) for unfavorable intermediate-risk prostate; late grade ≥3 GU/GI ~2.0%/1.1%, toxicity driven by dose and urethral constraints, not SBRT itself.
- HYDRA (MARCAP)PFS equal for isodose (HR 0.92) and dose-escalated MHFRT (HR 0.94) vs CFRT, but dose-escalated adds late G2+ GI toxicity (OR 1.48).
- SUPREMOCritique: the null tested chest-wall RT alone (RNI prohibited; SCV 12%, IMN <2%), not comprehensive PMRT; node-pos LRR still fell 4.8%→3.3% (HR 0.51).
- ESTRO Post-op Oral Cavity CTV GuidelinesPost-op primary CTV-P = (GTV-P pre-op +10mm) composited with (surgical defect/flap +5mm); first consensus method to standardize oral-cavity PORT delineation.
- ARS AUC: Intraprostatic Recurrence After RTConsensus AUC: PSMA PET + mpMRI + confirmatory biopsy before salvage reirradiation; short classic ADT preferred over ARSI, most regimens ≤6 fractions.
- 10-yr SBRT for Prostate Cancer (Nonrandomized Trial)10-yr RFS 90% (94% LR, 86% IR), OS 84%, late G3+ GI/GU ≤1.5% after 40Gy/5fx prostate SBRT, no ADT.
- NRG-GU005Bowel QoL MCID decline 35% vs 44% (p=0.034) favoring 5-fx SBRT; but DFS superiority not met (HR 1.38, futility) vs MH-IMRT.
- SUPREMO10-yr OS 81.4% vs 81.9% (HR 1.04, p=0.80): no survival benefit from post-mastectomy chest-wall RT in intermediate-risk disease.
- EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTUNo PFS/OS difference between RT (28×1.8 Gy) and dose-dense TMZ monotherapy in high-risk WHO grade 2 glioma; molecular subtype drives outcome.